Mylan Pharmaceuticals Inc. won the chance to knock out patents covering Teva Pharmaceutical Industries Ltd.’s new 40 mg/mL dosage of Copaxone (glatiramer) through the speedy inter partes review process.
The Patent and Trademark Office’s Patent Trial and Appeal Board issued a pair of Aug. 25 decisions instituting review of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?